Correlation between magnetic resonance imaging (MRI) findings and the new bone formation factor Dkk-1 in patients...

Area of Science:

• Rheumatology
• Immunology
• Radiology

Background:

• Spondyloarthritis (SpA) diagnosis increasingly relies on MRI.
• Anti-tumor necrosis factor (TNF) therapy is an established treatment for SpA.
• The role of Dickkopf-1 (Dkk-1) in SpA pathogenesis and treatment response requires further elucidation.

Purpose of the Study:

• To investigate the correlation between serum Dkk-1 levels and MRI findings in SpA patients undergoing anti-TNF therapy.
• To assess the impact of anti-TNF therapy on clinical, serological, and imaging markers of SpA activity.
• To explore the potential role of Dkk-1 as a biomarker for treatment response and new bone formation in SpA.

Main Methods:

• Prospective study of 30 active SpA patients treated with anti-TNF therapy (recombinant human TNF receptor-antibody fusion protein) for 6 months.
• Clinical, serological (ESR, CRP), and imaging (MRI of sacroiliac joints and spine) assessments were performed before and after treatment.
• Serum Dkk-1 concentrations were measured and correlated with clinical and imaging outcomes.

Main Results:

• Anti-TNF treatment significantly reduced inflammatory markers (ESR, CRP) and clinical indices (BASDAI, BASFI, ASDAS-CRP).
• Serum Dkk-1 levels, bone marrow edema scores in sacroiliac joints and spine significantly decreased post-treatment.
• Increased sacroiliac joint backfill scores were observed, and baseline/changes in serum Dkk-1 correlated with spinal bone marrow edema.
• Spinal bone marrow edema may predict new bone formation.

Conclusions:

• TNF inhibitors may reduce new bone formation in SpA by inhibiting serum Dkk-1 levels.
• Decreased Dkk-1 levels are associated with successful anti-TNF therapy in SpA.
• Spinal bone marrow edema on MRI is a potential predictor of new bone formation in SpA patients.